Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Predicted Market Size and CAGR of the Multiomics Market by the End of the 2029?
The multiomics market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to Increased biomedical research, increased government and private funding, a rise in the prevalence of chronic diseases, technological advancements, and enhanced computational tools and software for data analysis.
The multiomics market size is expected to see rapid growth in the next few years. It will grow to " $7.11 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to advances in artificial intelligence and machine learning, expansion of clinical applications, growing biopharmaceutical industry, emergence of integrated multiomics platforms, and increasing use in agricultural and environmental research. Major trends in the forecast period include technological advancements, the launch of new commercial multiomics platforms, the adoption of spatially resolved multiomics analysis, adoption in biopharmaceutical research and development, and expansion into clinical diagnostics.
Get your free report sample today:
Which Factors Are Contributing Most to the Expansion of the Multiomics Market?
The rising demand for personalized medicine is expected to propel the growth of the multiomics market going forward. Personalized medicine refers to a medical approach that customizes healthcare decisions and treatments to individual patients based on their genetic, environmental, and lifestyle factors. This personalized medicine approach is rising due to technological advancements, increasing demand for targeted therapies, and global healthcare improvements. Multiomics helps personalized medicine by providing a detailed understanding of an individual's genetic, molecular, and metabolic profile, enabling healthcare providers to tailor treatments based on the specific characteristics of each patient. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the multiomics market.
Which Key Segments Are Included in the Multiomics Market Analysis?
The multiomicsmarket covered in this report is segmented –
1) By Type: Single-Cell Multiomics; Bulk Multiomics
2) By Platform: Genomics; Transcriptomics; Proteomics; Metabolomics; Integrated Omics Platforms
3) By Application: Diagnostics; Drug Discovery And Development; Personalized Medicine; AgriGenomics; Other Applications
4) By End User: Academics And Research Organization; Pharmaceutical And Biotechnology Companies; Clinical research Organization; Other End-Users
Subsegments:
1) By Single-Cell Multiomics: Single-Cell Genomics; Single-Cell Transcriptomics; Single-Cell Epigenomics; Single-Cell Proteomics; Single-Cell Metabolomics
2) By Bulk Multiomics: Genomics; Transcriptomics; Epigenomics; Proteomics; Metabolomics
Which Emerging Trends Are Shaping the Future of the Multiomics Market?
Major companies operating in the multiomics market are developing advanced single-cell multiomics platforms to enable scientists to run large-scale studies without sacrificing sample integrity. Single-cell multiomics platforms integrate various omics with artificial intelligence capabilities, allowing users to seamlessly analyze and interpret complex biological data through sophisticated algorithms and machine learning techniques. For instance, in February 2023, Becton, Dickinson, and Company, a US-based medical device company, launched the BD Rhapsody HT Xpress, a high-throughput single-cell multiomics platform. This innovative system enables scientists to isolate, barcode, and analyze single cells at a high sample throughput, accommodating up to eight times more cells than previous versions of BD single-cell analyzers. The BD Rhapsody HT Xpress System ensures no sample loss, offering flexibility to analyze multiple samples and different cell sizes and types simultaneously, such as stem cells or cancer cells, enhancing researchers' ability to gain more insights in less time.
Who Are the Top Industry Players Driving the Multiomics Market Growth?
Major companies operating in the multiomics market are Bayer AG, Thermo Fisher Scientific Inc., Novartis AG, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Shimadzu Corporation, Bruker Corporation, Bio-Techne, Azenta Life Sciences, 10x Genomics, Ginkgo Bioworks, Abcam limited, BioLegend, Oxford Nanopore Technologies Plc, Adaptive Biotechnologies, Pacific Biosciences, Standard BioTools, Parse Biosciences, Mission Bio, CD Genomics, Singleron Biotechnologies, Psomagen, BGI Group
Get the detailed multiomics market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Multiomics Market?
North America was the largest region in the multiomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment